Print Preview Area

Outcome of therapy-related myeloid neoplasms treated with azacitidine
Journal of Hematology & Oncology, 08/02/2012

Fianchi L et al. – The study reports efficacy of azacitidine (AZA) in the largest series of therapy–related MN patients treated with 5–AZA. The data show that blasts and karyotype maintain their important prognostic role in t–MN also in the azacitidine era.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Physician Assistant Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Outcome of therapy-related myeloid neoplasms treated with azacitidine Journal of Hematology & Oncology, 08/02/2012

Outcome of therapy-related myeloid neoplasms treated with azacitidine
Journal of Hematology & Oncology, 08/02/2012